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Chapter 50
Treatment of Atrial Fibrillation 
and Atrial Flutter
Torsten Christ, Simon Pecha, and Norbert Jost
Abstract Atrial fibrillation (AF) is the most common arrhythmia in humans. 
Therapeutic goals are normalization of ventricular rate (rate control) or restoration 
of sinus rhythm (SR, rhythm control). Drugs can achieve both aims. Early thera­
peutic approaches included the use of plant glycosides, digitalis (from Digitalis 
lanata, Digitalis purpurea) for rate control and alkaloid, quinidine, for rhythm 
control. For the latter indication, sodium channel blockers became popular in the 
middle of the last century. However, awareness of disastrous ventricular proar­
rhythmia caused by sodium channel blockers in heart failure patients has reduced 
their use in AF. Amiodarone -  a mixed channel blocker -  is not associated with 
ventricular proarrhythmia, but its severe extracardiac toxicity limits its use in 
AF. Nevertheless, this compound has gained some popularity in treating atrial 
fibrillation and atrial flutter. Over the last two decades, intensive basic science 
research in the field of human atrial electrophysiology identified ion channels 
expressed selectively in the atrium but not in the ventricle (e.g., IKur, lK,Ach, SK 
channels). Those channels have gained enormous attention since they could repre­
sent targets for atrial antiarrhythmic drug therapy without the risk for ventricular
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arrhythmia. However atrial-selective expression of a given ion channel is not suf­
ficient to qualify it as a drug target. Blockade of atrial-selective ion channels 
should affect atrial electrophysiology to an extent sufficiently large to stop or to 
prevent AF. Blockers of IKur and IKAch have entered first trials in humans. 
Sarcoplasmic reticulum may represent another target. Enhanced spontaneous Ca2+- 
release from the sarcoplasmic reticulum may drive enhanced cardiac automaticity, 
which is believed to initiate and/or to maintain AF. Usefulness of such interven­
tions remains to be proven. Therefore, this chapter reviews classic antiarrhythmic 
drugs used in atrial fibrillation/flutter and some new compounds recently approved 
or under development.
Keywords Atrial fibrillation • Atrial flutter • Ion channel block • Proarrhythmic 
effects • Selectivity • Atrial selective
50.1 Introduction
Atrial fibrillation is characterized by extremely rapid, uncoordinated electrical 
activity of the atria. As a result, in the ECG regular P waves (Fig. 50.1) are lost. 
In AF, P waves are much more faster and irregular. Amplitude of P waves is 
clearly smaller in AF than in SR (Fig. 50.2). Uncoordinated electrical activity 
impairs mechanical function of the atria. Nevertheless, subsequent loss of atrial 
contractile performance leads, maybe somewhat unexpected, to only mild reduc­
tion in cardiac output. Critical reduction of cardiac output can occur when filling 
of the ventricles is compromised because of increased stiffness of the ventricles 
and/or ventricular inflow obstruction. The effect of AF on electrical activity of the 
ventricles depends on AV-conduction speed. The AV node cannot conduct faster 
than ~200 bpm to the ventricles, and slowing within the AV node is therefore 
essential to prevent atrial fibrillation which will lead to ventricular fibrillation, a 
serious rhythm disorder requiring immediate medical attention. The ventricular 
rate during AF may be within the physiological range but is often too fast. Since 
the speed of conduction within the AV node critically depends on the autonomic 
tone, in many patients with AF, the ventricular rate will increase quickly during 
exercise and/or anxiety, generating not only irregular but also a very fast heart­
beat. Often patients will be aware of AF because of the rapid and irregular ven­
tricular contractions. The highly irregular arterial pulse, termed “delirium cordis” 
or “arrhythmia absoluta,” is also one of the first clinical symptoms observed in 
patients with AF, a long time before it is recognized that atrial tachycardia is the 
cause of these symptoms. Consequently, slowing of the ventricular rate became 
the first goal in AF treatment and remained a mainstay up to now. Ultimately, the 
restoration of a normal sinus rhythm is the logical aim of any pharmacological 
intervention; however the risk-benefit ratio also has to be considered. This
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Fig. 50.1 Original ECG registrations from a patient in SR. Arrows indicate P waves. During nor­
mal sinus rhythm, P waves are upright in lead II and V2 and followed 1:1 by an QRS complex
chapter reviews the ion channels that affect atrial refractoriness and agents useful 
for terminating atrial fibrillation and atrial flutter and to prevent their 
reoccurrence.
50.2 Drugs Used for Rate Control
Many patients with a new-onset AF need slowing of the AV conduction (rate con­
trol), irrespective of whether restoration of the sinus rhythm will be a therapeutic 
goal. In patients, where sinus rhythm control is not a suitable treatment option, rate 
control may be a lifelong intervention. Digitalis glycosides were the first drug class 
used to treat patients with AF. Digitalis slows down AV-node conduction and 
thereby reduces the ventricular rate even during fast activation of the atria in AF. The 
enormous efficacy of this drug, with respect to slowing the heartbeat, is reflected in 
its name: “opium of the heart.” However, proper dosing has always been a challenge 
since digitalis glycosides have a rather slow and complex pharmacokinetic in con­
junction with a narrow therapeutic window that includes life-threatening side effects
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Fig. 50.2 Original ECG registrations from a patient with AF. Arrows indicate P waves are much 
faster, but smaller and QRS follows irregularly
[1]. Use of digitalis glycosides is safe when low doses are used and in some cases 
are controlled by monitoring serum levels of digoxin [2]. However, the vast major­
ity of electrophysiological effects of digitalis glycosides in different regions of the 
heart give concerns about general safety of that drug class. Prospective data about 
digitalis efficacy in patients with AF are not available. Recently published large 
retrospective study with sophisticated statistical methods applied clearly indicates 
negative outcomes for digitalis treatment in patients with AF [3]. Actual guidelines 
of AHA/ACC and ESC still recommend digitalis use for rate control in AF. However, 
irrespective of whether we will have hard prospective data in the future, we have to 
expect restrictions on the use of digitalis in patients with AF, since two other drug 
classes with a more favorable safety profile can now be used for rate control.
L-type Ca2+-channels critically regulate conduction in the AV node where Ca2+- 
channels instead of sodium channels conduct upstroke of action potentials. Two 
L-type Ca2+-channel blockers, diltiazem and verapamil, are able to provoke marked 
slowing of ventricular rate during AF [4, 5]. The ß-adrenoceptor antagonists slow 
down AV conduction especially when sympathetic tone is increased as in case of 
exercise or excitement. Keeping in mind the beneficial effects of ß-adrenoceptor 
antagonists in heart failure, this drug class is widely used in patients with AF and 
concomitant structural heart disease (~70 % in Europe). There are no obvious 
differences between different ß-adrenoceptor antagonists with respect to slowing 
down AV conduction (Chaps. 5 and 8).
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50.3 Antiarrhythmic Drugs
Atrial flutter is based on larger macro-reentry circuits compared to AF generating 
clearly distinguishable P waves in the ECG (see Fig. 50.3). Isolated atrial flutter is 
a rare condition [6]. AF and atrial flutter coexist in many patients. The larger reentry 
circuits in atrial flutter simplify treatment by catheter ablation and antiarrhythmic 
drugs. However, AF and atrial flutter probably respond to treatment aimed at pre­
vention of recurrence or improvement of survival and cardiovascular complications 
in a similar way and can be treated as one entity [7]. Therefore, we do not differenti­
ate between AF and atrial flutter. Classic antiarrhythmic agents can stop arrhyth­
mias. They do so as they have marked effects on the excitability of cardiac tissue. 
This intervention may be highly effective in acute settings, and even serious side 
effects may be accepted as long as treatment duration is short and physicians give 
the drug under controlled conditions.
1 sec
Fig. 50.3 Original ECG registrations from a patient with atrial flutter. Arrows indicate P waves 
there are much more P waves than QRS complexes. However, P waves are clearly distinguishable 
and are followed in a 3:1 or 2:1 mode by a QRS complex (best seen in V2)
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50.3.1 Class I Drugs
Efficacy of quinine to stop AF was first described in 1759 and introduced as a “pill 
in the pocket” approach for new-onset AF by a non-medic in 1922 [8]. Quinidine is 
the d-isomer of quinine, has a higher efficacy than quinine to stop AF, and was 
therefore used as an antiarrhythmic agent. From a general pharmacology perspec­
tive, quinidine shows a wide range of serious adverse effects. Quinidine affects 
gastrointestinal motility [9], and it should be noted that in the early days of quini- 
dine treatment dosage was increased up to the point when patients started to vomit. 
Transient thrombocytopenia and hemolytic anemia can occur [10]. Quinidine also 
blocks a-adrenoceptors [11] and muscarinic receptors [12]. Reflex release of cate­
cholamines upon vasodilation as well as release of inhibitory effects of acetylcho­
line will increase speed of AV conduction with a harmful increase in ventricular rate 
during AF. Increased AV conduction is especially harmful in the case of atrial flut­
ter, since ventricular rate can reach critical high values. Therefore, quinidine is often 
used in conjunction with other drugs that slow AV conduction. Pharmacokinetic 
properties gave rise to concern on its therapy. Quinidine has high plasma protein 
binding and can thereby increase serum levels of other drugs bound to plasma pro­
teins [13]. Cytochrome P450 enzymes extensively metabolize quinidine, and many 
of its metabolites show activity. Most importantly, quinidine can provoke life- 
threatening ventricular arrhythmias: torsades de pointes. The first ventricular proar­
rhythmic effects of quinidine were reported as early as in 1922. Systematic studies 
reveal an incidence of about 5 % [14]. Despite its unfavorable adverse effects, quini- 
dine is still recommended when other drugs have failed to convert AF since there is 
no doubt about its remarkable efficacy (see Chap. 48).
Quinidine and its congeners were later classified as so-called class I drugs since 
they slow maximum upstroke velocity of cardiac action potentials, indicating 
sodium channel block. The obvious efficacy of quinidine has gained enormous 
interest to search for class I drugs. The result of this effort resulted in a dozen of 
different class I drugs. From the point of cardiac cellular electrophysiology, they 
differ with respect to their effect on action potential duration (APD). So class I 
drugs were later subclassified (e.g., IA, IB, and IC; prolongation, shortening or no 
effect on APD). See Table 50.1 and also Chaps. 48 and 52.
However, it should be noted that the initial intention to search for congeners of 
quinidine was driven by the unfavorable selectivity profile regarding extracardiac 
targets and the slow pharmacokinetics of quinidine. Ajmaline, another plant alka­
loid, was a next, less toxic follower of quinidine [15]. It gained wide acceptance in 
Germany after successful self-experiments by the German cardiologist Kleinsorge, 
and details were published in 1954 [16].
Lidocaine was initially introduced as a local anesthetic in 1946 and first used as 
an antiarrhythmic agent in 1950 [17]. Its short half-life makes the drug attractive in 
emergencies, and the drug was used for many years in the clinical setting of acute 
myocardial infarction (even as intramuscular injection at that time). Lidocaine use 
in this indication was stopped because of excess mortality [18]. Lidocaine actions
Table 50.1 Summary of drags used for AF
Drag Introduced/approved Class iNa 1кг ÏRur l ïC A C h AR MR Noncardiovascular toxicity
Cardiovascular
toxicity
Quinidine 1918 IA + + + + «i + Thrombocytopenia, cinchonism, pruritus, rash QRS prolongation, 
torsades de pointes
Disopyramide 1962 IA + + + Anticholinergic effects, blurry vision Congestive heart 
failure exacerbation, 
torsades de pointes
Propafenone 1976 IC + + ß 1/2 Metallic taste, dizziness blurry vision, 
bronchospasm
QRS prolongation, 
congestive heart 
failure exacerbation
Flecainide 1975 IC + + Dizziness, headache, blurry vision QRS prolongation, 
excess mortality
Sotalol 1992 VT/VF 
2000 AF
II/III + ß 1/2 Bronchospasm Bradycardia, 
torsades de pointes
Ibutilide 1995 III + None Torsades de pointes
Dofetilide 2000 US only III + None Torsades de pointes
Amiodarone 1967 VT/VF only III + + Pulmonary (hypersensitivity pneumonitis, 
chronic interstitial infiltrates), hepatitis, thyroid 
(hypothyroidism or hyperthyroidism), 
photosensitivity, blue-gray skin discoloration 
with chronic high dose, nausea, ataxia, tremor, 
alopecia
Sinus bradycardia
Dronedarone 2009 III (+) + +
ß 1/2
Hepatotoxicity, anorexia, nausea; Sinus bradycardia
(continued)
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Table 50.1 (continued)
Drag Introduced/approved Class iNa 1кг ÏRur l ïC A C h AR MR Noncardiovascular toxicity
Cardiovascular
toxicity
Vernakalant 2010 Europe only New + + ( + ) ( + ) Dysgeusia, sneezing, paresthesia QT prolongation, 
hypotension
Ranolazine 2008 New + / + + ß 1/2 Dizziness, nausea, headache QT prolongation
Drags are listed based on their approval. Class means classification according the Vaughan Williams scheme. "New" means drags classified as new drugs not 
represented by the Vaughan Williams classification
IN a sodium current (peak), IKr delayed rectifier current, IKur ultrarapidly activating rectifier current, IK,ACh acetylcholine activated potassium current, AR 
adrenoceptor, MR muscarinic receptor. For further details, see text 
+ indicates blockade of the respective target
+/+ for ranolazine indicates blockade of both peak and late sodium current
y
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seem to be restricted to ventricles (see Chap. 48). Whereas lidocaine can prolong 
ERP in ventricular tissue [19], it was found almost ineffective in atrial tissue from 
the same species [20]. The reason for this finding remains unclear. One concern is 
that higher concentrations are needed to affect atrial relative to ventricular tissue. 
However, even almost neurotoxic concentrations of lidocaine are not able to convert 
AF in humans [21].
Disopyramide is another rather curious example. The drug can effectively stop 
AF, but its profound negative inotropic effects are troublesome [22]. Ironically, 
because of this “side effect,” disopyramide gained popularity in treating patients 
with hypertrophic cardiomyopathy. Disopyramide seems to be safe in patients with 
hypertrophic cardiomyopathy [23]. From the beginning, disopyramide’s marked 
antimuscarinic effects had limited patient acceptance [24]. However, this initially 
unwanted effect regained interest in some forms of vagally induced AF [25]. 
Disopyramide blocks many different potassium channels including IK,ATP [26]. 
Relevance of potassium channel blockade to its overall activity is unclear. 
Disopyramide was popular for conversion of AF in the 1980s but is no longer rec­
ommended in the North-American and European guidelines. It remains open to 
question if disopyramide may offer advantages in vagally induced AF.
Propafenone was tested in 1970s in Germany. It is structurally related to pro­
pranolol and blocks ßr  and ß2-adrenoceptors but not muscarinic receptors [27]. 
Propafenone is therefore classified as a mixture of a class I drug and a nonselective 
ß-adrenoceptor antagonist. It has gained wider acceptance and is still recommended 
as a second-line drug to convert AF in people without structural heart disease. Taste 
complaints represent a strange side effect [28].
Flecainide was the last compound labeled as class I drug and represents a 
remarkable advance in drug development. Flecainide shows high selectivity for 
sodium channels, and therefore unwanted effects are mainly restricted to sodium 
channel block in nerve cells. Such adverse effects occur in about 30 % of patients 
chronically treated with the drug and illustrate general limitations of sodium chan­
nel block [29]. Obviously unwanted effects can be reduced by administration on 
demand instead of continuous drug administration. The drug was initially approved 
to treat ventricular tachycardia and later for supraventricular arrhythmias. 
However, severe proarrhythmia in patients treated with flecainide after myocardial 
infarction stopped its use in this indication [30]. Putative causes for flecainide’s 
proarrhythmic action are discussed in hundreds of review articles (including in 
Chap. 48 of this book); however, the exact mechanism remains unclear. It should 
be noted that flecainide proarrhythmia could not be reproduced in a sophisticated 
rat model of myocardial infarction [31]. The latter rather surprising finding led to 
the idea that the proarrhythmic effect of flecainide may be mediated rather via 
blockade of other channels than sodium channels such as the hERG (not func­
tional in rat heart). Nevertheless, use of flecainide is no longer accepted in patients 
with compromised ventricular function. Since many younger patients suffering 
from AF are free of structural heart disease, flecainide is becoming a popular drug 
in such patients. There is a consensus that flecainide seems to be safe in this popu­
lation [32].
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50.3.2 Class II Drugs
The ß-adrenoceptor antagonists were initially reported as class II antiarrhythmic 
drugs. Obviously, they do not affect excitability of cardiomyocytes directly, but can 
prevent harmful arrhythmogenic actions of endogenously released catecholamines. 
Therefore, they are not able to stop arrhythmias in general. Efficacy of prophylactic 
ß-adrenoceptor antagonist treatment is restricted to situations where AF is the result 
of acute stress such as postoperative atrial fibrillation [33]. Besides this indication, 
the efficacy of ß-adrenoceptor antagonists in AF is not convincingly proven. Even in 
the setting of heart failure, where catecholamine levels are clearly elevated, 
ß-adrenoceptor antagonists do not have any impact on the occurrence of AF [34, 35].
50.3.3 Class III Drugs
Sotalol (MJ 1999) is the oldest class III drug [36]. It was initially developed as a 
competitive ß-adrenoceptor antagonist and was intensively tested for its ability to 
prevent ventricular arrhythmias in the setting of experimental myocardial infarction 
(so-called class II action) [37]. Somewhat unexpected for a ß-adrenoceptor antago­
nist, sotalol was not only effective against arrhythmias but caused a remarkable 
positive inotropy. The surprising finding could be later explained by APD prolonga­
tion. Sotalol blocks potassium currents that are active during the plateau phase (later 
identified as IKr, conducted via hERG channels) (see Chap. 48). The use of sotalol 
was not widely propagated until the early 1990s, when class I drugs had lost accep­
tance in ventricular arrhythmias and the compound was believed to fill the gap. To 
avoid the harmful negative inotropy of ß-adrenoceptor antagonists that are given 
acutely in patients with heart failure, the (d)-enantiomer of sotalol, devoid of adre­
noceptor antagonist activity but still blocked potassium channels, was introduced to 
clinical use. However, it became quickly clear that (d-)-sotalol provoked severe ven­
tricular proarrhythmia not only in patients with heart failure [38] but also in an 
animal model with left ventricular hypertrophy [39]. This quickly resulted in the 
loss of status for racemic sotalol in the treatment of ventricular tachycardia. 
Subsequently, sotalol was tested for its anti-AF activity [40]. Racemic sotalol is still 
frequently used for the prevention of reoccurrence of AF [41]. Its role in converting 
recent-onset AF is less popular. There are theoretical considerations in the use of 
sotalol for that application. Any (even electrical) conversion of AF can be followed 
by severe sinus bradycardia or even sinus arrest [42]. ß-Adrenoceptor antagonists 
are expected to aggravate such a scenario. Since most of the class III agents show 
the phenomena of reverse-use dependence with excessive APD prolongation at low 
heart rate, occurrence of torsades de pointes arrhythmia is facilitated [43]. This 
phenomenon was realized as a dangerous scenario since the 1960s when quinidine 
(a potent hERG blocker) was frequently used for conversion of AF [44]. From this 
background, a fixed combination of hERG block with a ß-adrenoceptor antagonist 
may be at least questionable. Nevertheless, application in patients with AF is still
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popular, for example, in the United States [45, 46]. There is a consensus that sotalol 
should not be used in case of left ventricular hypertrophy or left ventricular failure.
Amiodarone is another agent classified as a class III antiarrhythmic drug. It was 
initially developed as a vasorelaxant. The very first study about amiodarone effects 
on AP showed marked APD prolongation without obvious effects on upstroke 
velocity [47]. Therefore, amiodarone was classified as a so-called class III drug 
(APD prolongation only). More than 15 years later, patch-clamp studies revealed 
sodium as well as calcium channels blocked by amiodarone [48]. Sodium channel 
block was later found to be use dependent and stronger at depolarized membrane 
potential [49, 50]. Thus, amiodarone shares typical class I drug features. In addition 
to the block of ion channels, amiodarone acts as an antagonist at ß-adrenoceptors 
[51]. The relative contribution of different targets affected for the overall activities 
is less clear, but the blockade of sodium channels may play an important role (com­
pare dronedarone section). Severe hypotension that results because of vasorelax­
ation, might complicate its use, when given as rapid intravenous injection. The 
biggest advantage of amiodarone compared to class I drugs is its low incidence for 
ventricular proarrhythmia [52]. The reason for the difference compared to other 
class III drugs is unclear [43]. The almost unique feature among antiarrhythmic 
drugs made amiodarone very attractive when it becomes clear that class I drugs 
have failed in patients with ventricular arrhythmias and structural heart disease. 
Consequently, amiodarone was approved for the treatment of life-threatening ven­
tricular arrhythmias. After successful introduction of implantable cardioverter/defi- 
brillators, amiodarone (like any other antiarrhythmic drugs) has lost popularity in this 
field (Chap. 8). Amiodarone not only suppresses ventricular arrhythmias but also 
prevents the recurrence of AF. In addition, amiodarone can convert AF; however, 
the onset of effect is delayed compared to class I drugs (hours vs. minutes). Low 
propensity for ventricular proarrhythmia makes amiodarone very attractive for 
treating AF, but the drug was never approved for this indication. Nevertheless, off­
label use to prevent reoccurrence of AF is enormously popular (~60 % of all pre­
scriptions in one US population) [45], but needs careful consideration given its 
extracardiac toxicity. Some of the unwanted effects are rather irreversible and even 
life threatening. Many of the amiodarone toxic effects are described as cumulative 
toxicity, and that could be reduced by lower dosages and shorter duration of treat­
ment. Obviously, amiodarone use in younger patients is problematic. Large retro­
spective trials suggest that a remarkable number of younger patients are treated with 
amiodarone. Many of them are expected to be free of structural heart disease and 
could therefore be treated with less toxic class I drugs [46]. There are other issues 
that need to be addressed. In case of AF, relapse under continued treatment with 
amiodarone, the indication to continue drug application has to be carefully checked. 
There is no doubt that amiodarone can slow AV conduction and thereby control rate 
during AF. However, drugs much less toxic can achieve this goal; amiodarone is not 
recommended for this indication. Besides, in any controversy about the appropriate 
indication for amiodarone in AF, there is a general consensus that chronic amioda- 
rone treatment needs intense follow-up. Patients have to undergo several clinical 
and biochemical tests at a fixed time schedule [53]. One of the most disastrous side
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effects of amiodarone is its thyrotoxicity. Therefore, it is logical to search for a 
compound that is structurally related to amiodarone but free of iodine.
Dronedarone is the result of such effort, and like its congener amiodarone, 
dronedarone blocks a number of different ion channels and adrenoceptors. From 
the viewpoint of cellular electrophysiology, dronedarone shares many acute 
effects of amiodarone (e.g., APD prolongation), but it lacks pronounced sodium 
channel block as seen after chronic treatment with amiodarone [54]. Based on 
clinical results with amiodarone, it is logical to use dronedarone in patients with 
heart failure in order to reduce sudden cardiac death. However, the drug failed in 
this indication because of causing excess mortality due to worsening of heart 
failure [55], and it is noteworthy that the dronedarone, in contrast to its closely 
related parent compound amiodarone, was never approved for ventricular arrhyth­
mias. The next step was testing dronedarone for its activity in AF. Like amioda­
rone, dronedarone is able to convert recent AF [56], but dronedarone, too, was 
never approved for that indication. Dronedarone prolongs the time to AF recur­
rence after conversion of AF [57], and the drug was approved by fast track in 
2010 for that indication. Dronedarone is clearly less effective compared with 
amiodarone [58]. In rare cases, dronedarone can induce liver injury, including 
even several cases of acute liver failure leading to liver transplants [59]. Recently 
FDA addressed these life-threatening events in a warning letter (http://www.fda. 
gov/Drugs/DrugSafety/ucm240011.htm). Dronedarone can increase mortality in 
some patients with permanent AF, and serious safety concerns lead to restrictions 
in its use (http://www.fda.gov/Drugs/DrugSafety/ucm264059.htm). Dronedarone 
is recommended as first-line therapy to prevent reoccurrence of AF. However, 
even if excess mortality is restricted to some patient populations (severe heart 
failure, persistent AF), it remains questionable whether a drug that can cause 
such harm should be prescribed for an arrhythmia that is not directly life threat­
ening. Dronedarone has many pleiotropic effects, which are recently summarized 
in an excellent review [60]. What role of dronedarone should be in the treatment 
of AF remains to be determined. However, one can conclude that the initial hope 
to get a substitute for amiodarone that combines the advantages of amiodarone 
(efficacy against VF and AF without ventricular proarrhythmic potency) with the 
advantages of advanced drug design (freedom of extracardiac toxicity) could not 
yet be achieved.
Dofetilide and ibutilide are structurally related to the experimental hERG blocker 
E-4031, and all of these compounds show high selectivity. In contrast to class I 
drugs, pure hERG blockers do not lead to CNS side effects. Both dofetilide and 
ibutilide can effectively stop AF and prevent reoccurrence of AF [61, 62]. However, 
since blockade of hERG channels is now recognized as the leading cause for drug- 
induced proarrhythmias in general [63], the acceptance for that drug class is very 
limited (see Chaps. 48 and 49). In some countries, both drugs were never approved 
for AF. On the other hand, several studies report dofetilide as a safe drug as long as 
dosage is adjusted carefully based on QT measurements even in patients with left 
ventricular dysfunction [64].
50 Treatment of Atrial Fibrillation and Atrial Flutter 1071
50.4 Novel Targets Sites: Atrial-Selective Ion Channel Block
50.4.1 Potassium Currents
50.4.1.1 Ultrarapidly Activating Potassium Current (IKur)
In the human heart, the shape of the action potentials differs remarkably between 
atrium and ventricle (Chap. 46). While ventricular action potentials show a long- 
lasting plateau phase at positive membrane potentials, atrial repolarization is charac­
terized by a pronounced phase I repolarization leading to a deep notch with a plateau 
voltage clearly in the negative range. One reason for this difference is the existence 
of IKur, encoded by Kv1.5, in atria only [65]. Therefore, blockade of IKur represents a 
promising example of an atrial-selective ion channel block target [66]. IKur blockade 
increased the force of contraction in atrial tissue from patients in SR as well as in AF 
[67], and this helped to reverse contractile dysfunction in AF. However, there are 
several limitations. Whereas the first report in a goat model of AF showed a clear 
increase in refractoriness upon mixed Ito/IKllr block by AVE0118 [68], the same com­
pound rather shortened APD90 in atrial tissue obtained from patients with SR [69]. 
Reduced expression of Kv1.5 in AF and inactivation of IKur at higher rates in AF [70] 
have questioned the value of Kv1.5 as a drug target for AF. Besides this theoretical 
consideration, Kv1.5 blocker prolongs APD90 in AF. Recent in vitro study implicate 
effectiveness in human atrial tissue even at higher rates underlying the importance 
of rather complex interactions complicating prediction of drug effects based on 
patch-clamp data. One of the most advanced IKur blockers such as D0103 (Xention 
Ltd, UK) has now progressed to first studies in man [71].
50.4.1.2 Acetylcholine-Activated Potassium Current (IK,ACh)
Even in the first reports of electrical remodeling in human AF, an increased inward 
rectifier current was described [72]. Later it was suggested that not only the increased 
expression of Kir 2.1-2.4 encoding IK1 was responsible, but also the existence of 
constitutively active IKACh could be an underlying cause [73]. This concept has raised 
enormous interest, since blockade of constitutively active IKACh could represent not 
only atrial selective (IK,ACh believed to be expressed in the atrium only) but also AF 
selective (IKACh becoming constitutively active in AF). The former assumption has 
been questioned recently by the finding that highly selective blockers of IKACh can 
affect ventricular action potentials [74]. However, it should be noted that experi­
ments were performed in rat ventricles. Regarding the latter findings, it should be 
noted that in dogs, blockade of IKACh prolongs atrial APD even in tissues obtained 
from control animals, which reveals important species differences [75]. Reports of 
in vitro effects of IKACh blockers on human atrial tissue are still lacking. First report 
on in vivo effects of IKACh blockers in humans gave disappointing results [76], ques­
tioning whether the effect size is sufficient to evoke robust effects on refractoriness.
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50.4.1.3 Calcium-Activated Potassium Channels
Small-conductance calcium-activated potassium channels (SK), also named calcium- 
activated potassium channels, were first described in the CNS where they contribute 
to transient hyperpolarization following an action potential [77]. Availability of selec­
tive blockers of SK has gained interest. SK channels are expressed in cardiomyo­
cytes, and their activity showed the expected calcium dependency [78]. Interestingly, 
SK blockers prolong APD in atrial but not in ventricular tissue obtained from humans 
[79]. This finding makes SK channels highly attractive as an atrial-selective antiar­
rhythmic intervention. SK channel block has clear antiarrhythmic affects in different 
animal models. In human atrial tissue, SK expression was found to be reduced in AF 
[79]. Overall, the relevance of SK block for excitability in human atrium at higher 
rates and at increased intracellular calcium concentrations needs to be determined.
50.4.2 Atrial-Selective Sodium Block
50.4.2.1 Late Sodium Current
Sodium currents are known to activate and inactivate very quickly within a few mil­
liseconds. However, a small amount of sodium currents may not inactivate completely 
during a test pulse and is therefore called late sodium current (INajate). Definition and 
quantification of INaJate varies, but most importantly INaJate was found to be increased in 
atrial myocytes obtained from patients with AF compared to those from SR [80]. 
Ranolazine was used in a vast majority of in vitro studies as a selective blocker of 
INaJate. This assumption is based mainly on data from patch-clamp studies where rano­
lazine shows selectivity for INaJate over INapeak [81]. However, in intact cardiac muscle 
preparations, ranolazine depresses maximum upstroke velocity in a use-dependent 
manner [82]. This prototypical class I activity occurs in the same concentration range 
where it blocks INaJate [80]. Thus, discrimination between effects on INapeak and INaJate is 
complicated. Furthermore, ranolazine blocks hERG channels [83] and ß-adrenoceptors 
[84, 85]. These findings suggest that ranolazine pharmacodynamics is similar to that 
of propafenone. Although ranolazine has antiarrhythmic activities [86], it is hard to 
say to what extent it relates to the blockade of INaJate. From the general pharmacody­
namics perspective, it would be of interest to have more selective blockers of INaJate 
available, at least as a tool to study physiological importance of INaJate in human heart 
under physiological and pathophysiological conditions.
50.4.2.2 Peak Sodium Current
Blockade of sodium channels is highly effective in converting AF. Therefore, 
sodium channels may remain an interesting drug target. Atrial-selective actions 
could be achieved when the sodium channel blocker has a higher affinity for sodium
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channels in atrium than in ventricle, but this has never been shown. Differences in 
biophysics per se or different channel properties because of differences in mem­
brane voltages from where they operate can modulate channel function, and drug 
binding is another possibility. Early studies in human cardiomyocytes showed not 
only identical current densities in atrial compared to ventricular cells but also simi­
lar voltage dependency of activation and inactivation [87, 88]. However, on the level 
of action potentials, it was consistently demonstrated that the resting membrane 
potential in atrial tissue was about 5 mv less negative than in ventricular [79, 89] 
tissue. Thus, more sodium channels should be inactivated in the atrium resulting in 
a higher affinity for sodium channel blockers. For ranolazine, it was proposed to 
block preferentially atrial sodium channels because of different resting membrane 
potential [90]. However, modifying resting membrane potential alone has hardly 
any effect on the absolute reduction in maximum upstroke velocity evoked by rano­
lazine [82]. Sodium channel blockers can shift steady-state inactivation curves to 
more negative potentials and thereby bring more channels to an inactivated state at 
any given membrane potential. Such shifts by ranolazine was reported to be larger 
in atrial than in ventricular dog myocytes [90]. In contrast, even in the same species 
(dog), effects of ranolazine on maximum upstroke velocity were almost identical in 
size when measured in atrial and ventricular tissue [82]. At present, atrial preferen­
tial blockade of INapeak by ranolazine seems rather unlikely.
50.5 Newly Approved Drugs: Classification 
Under Discussion
50.5.1 Vernakalant
Vernakalant consists to the bulk of agents initially developed as blockers of IKur [91] 
and thereby promising atrial-selective increase in refractoriness. It was approved in 
Europe as intravenous injection for the acute conversion of AF. Vernakalant’s effi­
cacy is not inferior to class I drugs such as propafenone and flecainide [92, 93]. 
Proper classification of the drug remains problematic since the blockade of IKur in 
human atrial cardiomyocytes is small and the effect on the shape of AP is very little 
compared to other IKur blockers [94]. Clinically proven antiarrhythmic efficacy is 
most probably the result of use-dependent depression of maximum upstroke veloc­
ity indicating relevant sodium channel block [94]. Sodium channel blockade-related 
effects such as conduction delay and negative inotropy were reported in atria and in 
ventricles [95, 96] and that resembled the effect of flecainide arguing against atrial- 
selective sodium channel block. APD in human atrial tissue is slightly prolonged 
because of hERG channel block [94] so vernakalant would be classified as class IC 
(like flecainide) in earlier days. Blockade of IKACh by vernakalant is sometimes used 
as another argument to classify the drug as an atrial-selective antiarrhythmic agent. 
However it should be noted that even flecainide blocks both IKACh and IKur [97, 98]. 
Intravenous vernakalant converts AF faster than oral propafenone and flecainide
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[92, 93]. This finding just illustrates basic principles in pharmacokinetics (faster 
onset of drug effect when applied intravenously compared to oral) than it indicates 
general superiority of vernakalant over older, nicely established drugs. Taken all of 
these into consideration, we may say that it is least questionable whether vernaka­
lant represents a major advantage in pharmacological conversion of AF.
50.6 Novel Targets: Kinases
One reason for the disappointing high relapse rate under “conventional” antiar­
rhythmic drug therapy could be the fact that the ion channel blocking effect just 
limits excitability but lets the assumed trigger event -  generation of spontaneous 
impulse -  untouched. Impulse formation within (atrial) working myocardium can 
occur when -  after a regular action potential -  a critical amount of Ca2+ is released 
from the sarcoplasmic reticulum, sufficiently large to generate a critical depolariz­
ing net inward current that leads to depolarization with a subsequent additional 
action potential [99]. Catecholamines are known to promote that mechanism, and it 
is assumed that many of the targets involved are activated because they are phos- 
phorylated by protein kinase A (PKA) and/or Ca2+/calmodulin-dependent kinase II 
(CaMKII). Both PKA and CaMKII-dependent targets have been reported to be 
hyperphosphorylated in atrial tissues obtained from patients with AF. Consequently, 
it was proposed to block kinase as a causative therapeutic intervention in AF [100]. 
However, others could not confirm this increased target phosphorylation in AF 
[101]. More importantly in an animal model on AF, Ca2+-signaling was found to be 
“silenced,” [102] and arrhythmias were absent in atrial tissue from patients with AF 
[101] suggesting that abnormal impulse generation within the atrial tissue may not 
be the leading cause for the maintenance of AF in humans.
50.7 Concluding Remarks
From a historical point of view, pharmacological treatment of AF starts with the 
slowing of AV conduction and blockade of sodium channels to convert AF. Both 
objectives can now be achieved by employing drugs, which are less toxic than those 
were previously used. In spite of remarkable advantages in drug development, avail­
able options still show drugs with limited efficacy and serious adverse effects. 
Decision making in individual patients should be based on regularly updated guide­
lines published by AHA/ACC and ESC [103, 104]. It should be noted that such 
guidelines not only reflect scientific points but also discuss differences in regulatory 
aspects and availability of drugs in different countries [105]. Intensive basic science 
work in human atrial tissue as well as the use of sophisticated animal models for AF 
have identified new putative targets to gain atrial-selective antiarrhythmic drugs 
[106]. As a result of these intensive investigational and developmental works, the
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first agents have reached the level of clinical application. Future research will show 
if the new drug targets can help to increase the efficacy and safety of pharmacologi­
cal treatment of AF.
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